CP-1

CP-1 is a synthetic research peptide utilized as a negative control in preclinical investigations of Alzheimer's disease therapeutics, specifically those targeting neuroinflammation via Glucocorticoid-induced leucine zipper (GILZ) analogs. It is a scrambled or mutated variant of the active GILZ analog peptide (GA), engineered to be biologically inactive and lacking the ability to bind the activated NF-κB p65 transcription factor. In animal models such as the 5xFAD mouse, CP-1 is administered intraperitoneally to establish a baseline for non-specific peptide effects, thereby validating that the therapeutic outcomes observed with active analogs—such as reduced gliosis and amyloid-beta deposition—are due to specific inhibition of the NF-κB pathway. As a control compound, it has no therapeutic efficacy and is not intended for commercial or clinical development.

Other names

control peptide 1scrambled GILZ analog peptide